Oct 172017
 

via Abundant Life Wellness Center

A seasonal flu shot is a bit like a local weather forecast: Based on the conditions elsewhere and the direction of the prevailing wind, a meteorologist can give the public a pretty good idea of what to expect in the near future. Experts who track influenza’s intercontinental travels basically do the same thing.

“Epidemiologists monitor what strains of influenza are circulating in Southeast Asia. … they usually choose three or four of them, and they predict what the prevailing circulating strains will be,” said David Putnam, associate professor in the Nancy E. and Peter C. Meinig School of Biomedical Engineering.

“Usually they’re right, but sometimes they’re wrong,” Putnam said, “and it changes every year because proteins in the virus mutate.”

But certain proteins in the influenza virus remain constant year after year. And Putnam and Matt DeLisa, the William L. Lewis Professor of Engineering in the Robert Frederick Smith School of Chemical and Biomolecular Engineering, are taking one of those conserved proteins, Matrix-2 (M2), and packaging it in a nanoscale, controlled-release “capsule” in an attempt to create a quick-acting, long-lasting, multi-strain vaccine against pandemic influenza A.

The capsule is a bacterial outer membrane vesicle (OMV), which DeLisa and Putnam have developed collaboratively for several years. The OMV is a membrane-based nanostructure, in this case engineered from nonpathogenic E. coli, whose outer surface mimics the cell from which it originated.

Their paper, “A Single Dose and Long-Lasting Vaccine Against Pandemic Influenza Through the Controlled Release of a Heterospecies Tandem M2 Sequence Embedded Within Detoxified Bacterial Outer Membrane Vesicles,” appears in the journal Vaccine. First author is Hannah Watkins, Ph.D. ’17, now a postdoctoral researcher at the Massachusetts Institute of Technology.

The influenza A virus is a moving target. It changes year to year, and can morph into a pandemic – infectious across a large region – strain that can put the general population at risk. The Putnam-DeLisa team is leveraging the versatility of OMVs, which have shown promise against other deadly pathogens, to create a single-shot vaccine.

The M2 protein is found evolutionarily in the influenza sequence in birds, pigs and humans, so the group took two sequences from birds, one from pigs and one from humans, and assembled them into one multitarget antigen.

“So even if, say, the human strain mutates,” Putnam said, “we know where it came from and it’s going to look like the other two. We kind of covered all the bases.”

In testing, mice infected with the influenza A virus developed high antibody counts just four weeks after vaccination, compared with eight weeks from a typical multishot (prime/boost) vaccine regimen. And the protection was long-lasting: After six months, all of the test mice given the OMV vaccine survived a lethal influenza A infection.

Six months is approximately 25 percent of the typical life expectancy for a mouse, so Putnam thinks it is likely that this OMV-based vaccine would be long-lasting for humans, too.

“Even if we have to give a booster shot every 10 years, like tetanus, that’s still very good,” he said. “Theoretically it should last a long time.”

Additionally, since the vaccine cocktail is encapsulated in a bacterial vesicle, there’s no need for an adjuvant – an agent that’s added to most vaccines to boost the body’s immune response. The immune response is enhanced by the bacteria from which the OMV is derived.

“As a result, formulating and manufacturing of controlled-release OMVs should be more cost-effective,” DeLisa said.

Learn more: A new kind of influenza vaccine: One shot might do the trick

 

The Latest on: Multi-strain flu vaccine
  • Israeli Super-Vaccine for Flu Reported, Investors Happy
    on November 17, 2017 at 4:00 pm

    Nevertheless, the company says its universal multi-season/multi-strain flu vaccine will greatly enhance the average person's immune system, enabling patients to receive a single shot once every few years that will protect them against most forms of influenza. […]

  • Researchers Working on Single-Dose, Long-Lasting Flu Vaccine
    on October 23, 2017 at 1:00 am

    The researchers from Cornell are taking one of those proteins and packaging it into a nano-size, controlled-release capsule in the hopes of creating a long-lasting multi-strain vaccine against influenza A. The time-release capsules mimic a vaccine booster ... […]

  • Flu jab 2017: Boost effectiveness of vaccine by taking THIS trendy supplement
    on October 18, 2017 at 12:01 am

    Flu jabs are set to be particularly important this year with the Aussie flu on its way and the NHS warning the health service will be inundated with ill patients. However, the effectiveness of the vaccine ... species from a multi-strain probiotic. […]

  • Could a longer-lasting flu shot be a reality in the future?
    on October 10, 2017 at 11:53 pm

    Their hope is that the new shot will be a quick-acting, long-lasting, multi-strain vaccine against influenza A, and would mean maybe just one jab would be sufficient for protection. The influenza A virus can be described as a “moving target” as it ... […]

  • Do you suffer from the flu every winter? A new shot may protect you for years
    on October 10, 2017 at 10:55 pm

    multi-strain vaccine against influenzaA, and would mean maybe just one jab would be sufficient for protection. The influenza A virus can be described as a “moving target” as it changes from year to year and can morph into a pandemic strain — meaning ... […]

  • A New Kind of Influenza Vaccine: One Shot Might Do the Trick
    on October 8, 2017 at 2:05 pm

    multi-strain vaccine against pandemic influenza A. The capsule is a bacterial outer membrane vesicle (OMV), which DeLisa and Putnam have developed collaboratively for several years. The OMV is a membrane-based nanostructure, in this case engineered from ... […]

  • A new kind of influenza vaccine: One shot might do the trick
    on October 7, 2017 at 5:00 pm

    multi-strain vaccine against pandemic influenza A. The capsule is a bacterial outer membrane vesicle (OMV), which DeLisa and Putnam have developed collaboratively for several years. The OMV is a membrane-based nanostructure, in this case engineered from ... […]

  • BiondVax surges after results of flu vaccine study
    on July 19, 2017 at 9:19 pm

    “These significant results confirm that the M-001 is a unique and innovative influenza vaccine that elicits strong T-cell responses and is expected to provide multi-strain and multi-season protection against influenza illness,” said Tamar Ben-Yedid ... […]

  • Flu: Breakthrough as multi-strain vaccine raises prospect of 'universal' protection against virus
    on August 24, 2015 at 9:03 am

    Scientists have developed a flu vaccine that works against more than one strain of the influenza virus which has raised the prospect of a “universal” vaccine against all types of flu. Currently, seasonal flu vaccines are designed against specific viral ... […]

via Google News and Bing News

Other Interesting Posts

Leave a Reply

%d bloggers like this: